A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
Inclusion Criteria:
Exclusion Criteria:
Ciudad de Buenos Aires, C1430EGF, Argentina
Campinas, 13060-904, Brazil
Salvador, 41500-300, Brazil
Hradec Kralova, 500 02, Czechia
Fujiidera-shi, 583-0027, Japan
Higashiibaraki-gun, 311-3193, Japan
Kumagaya-shi, 360-8567, Japan
Shimotsuga Gun, 321 0293, Japan
Shinjuku Ku, 162 8655, Japan
Sumida Ku, 130 8575, Japan
Sunto-gun, 411-8611, Japan
Aydoun, 21166, Jordan